Background Erlotinib and gefitinib are weak base drugs whose absorption and clinical
efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton …

Background Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …

Purpose: Erlotinib and gefitinib are both tyrosine kinase inhibitors (TKIs) approved for the
treatment of non-small cell lung cancer (NSCLC). Although it is well known that the increase …

Objectives As the bioavailability of erlotinib is dependent on gastric pH, an increase in
gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce …

Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …

Background The use of gastric acid suppressants (GASs) has an influence on the exposure
of some epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and …

Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …

Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …

The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the
epidermal growth factor receptor (EGFR) has revolutionized the management of non-small …

Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause
of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of …